Received Apr 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 6 | B0005 | IM / RA |
| FLU3 | INFLUENZA (SEASONAL) (FLUCELVAX) | SEQIRUS, INC. | N/A | 391417 | IM / RA |
No adverse event reported. Reporting per Moderna after a temperature excursion, vaccine remained viable after the excursion per Moderna.
Activity intolerance
PVD, pulmonary embolism, vascular insufficiency, asymptomatic varicose veins of right lower extremity, bunion of right great toe, chronic bilateral low back pain without sciatica, RLS, idiopathich chronic gout, bilateral lower limb edema, pain of right lower extremity, essential tremor, pruritus vulvae, drug-induced diabetes mellitus, iatrogenic pulmonary embolism and infarction, chronic respiratory failure with hypoxia and hypercapnia, PTSD, schizotypal personal disorder, anxiety state, OCD, morbid obesity, insomnia, unsteady gait
gabapentin, fluvoxamine, ziprasidone, torsemide, potassium chloride, diclofenac sodium, clotrimazole cream, sodium chloride nasal spray, ura, benzonatate, albuterol HFA, zinc oxide ointment, ascorbic acid, chlorhexidine gluconate,
oxycodone, glipizide, metformin
N/A